Navigation Links
Use of clot-busting drug for US stroke patients doubled from 2005 to 2009
Date:6/2/2011

CINCINNATIIn a review of nationwide hospital databases, University of Cincinnati (UC) emergency medicine and neurology researchers have found that the rate of treatment with the standard therapy for acute ischemic stroke patients has doubled since 2005.

Their paper, "Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States," is published online ahead of print in the journal Stroke. The study estimates between 23,800 and 36,000 U.S. patients received rtPA treatment in 2009up from between 10,800 to 12,600 in 2004.

Since its approval by the Food and Drug Administration in 1996, recombinant tissue-type plasminogen activator (rtPA) remains the only FDA-approved therapy for treatment of acute ischemic stroke (AIS), caused by blocked blood flow in the brain. The clot-busting drug can decrease the likelihood of disability in stroke patients, but only when administrated intravenously within hours of the stroke.

However, treatment rates of rtPA remain relatively low, says lead author and UC assistant professor of emergency medicine and neurosurgery Opeolu Adeoye, MD, mainly because many patients do not arrive to the hospital in time to receive the drug. There are also a number of exclusions for rtPA, based on bleeding risks, recent surgery and other factors.

Previous UC research using the Medicare Provider and Analysis Review and a privately maintained hospital database concluded that, from 2001-2004, between 1.8 percent and 2.1 percent of AIS patients received the thrombolytic drug. Using data from the same databases, Adeoye and colleagues sought to update those figures in this new study. Their results show a significant jumpin 2009, 3.4 percent to 5.2 percent of AIS patients in the U.S. received rtPA, approximately double the rate of treatment in 2005.

Adeoye writes that the jump is "strikingly different" from the previous study, which documented essentially no rise in rtPA treatment rates between 2001 and 2004.

He suggests several factors may account for the increase, including formal certification of hospitals as stroke centers and aggressive public campaigns by the American Heart Association to educate both health care providers and patients on signs of a stroke and the latest clinical guidelines.

In the publication, Adeoye notes that the figures in the database are subject to billing error; however, no other practical means exist for obtaining nationwide estimates of rtPA use.

As far as what the results say about the state of stroke care in the U.S., Adeoye says it's clear that providers are making progress, but they still have a long way to go.

"The biggest thing is making sure patients are at the hospital within the time frame required to receive the treatment," he says. "We need to help educate the public on rapid recognition of stroke symptoms and improve transportation rates to stroke-ready hospitals."


'/>"/>

Contact: Katy Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. More Stroke Patients Get Clot-Busting Drug But Barriers Remain
2. How well does clot-busting drug work in stroke patients?
3. Longer Time Frame for Clot-Busting Drug May Help Beat Stroke
4. Early Treatment With Clot-Busting Drug Best After Stroke
5. U.S. Southeast Stroke Belt Also Shows Higher Rates of Cognitive Decline
6. Experts Say Stroke Care Differs for U.S. Minorities
7. Cognitive decline incidence higher in Southern stroke belt
8. Stroke Patients May Regain Function Just as Easily at Home
9. New Canadian blood pressure education program a powerful tool in fight to reduce stroke
10. Study Finds Aspirin Still Best at Preventing 2nd Stroke
11. Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: